Glaxo backs $60M biotech cluster project; Amarin raises $70M;

> In an effort to create a new biotech cluster which can eventually rival Boston's, GlaxoSmithKline is joining hands with the British government, the nonprofit Wellcome Trust and the East of England Development Agency to create a new science park that will eventually become home to 1,500 scientists devoted to new drug development. Altogether, the three groups will chip in close to $60 million in cash and facilities to create the hub at Glaxo's site near Stevenage. Report

> Amarin says it has arranged a private placement to raise $70 million. The money is earmarked for late-stage studies of AMR101 in patients with high triglyceride levels and mixed dyslipidemia. Release

> Fast-rising shares of Compugen jumped again this morning after the developer announced that it had reached an agreement with Bayer on the further evaluation of a tumor target that it had originated. Report

> Texas-based Phyton Biotech is buying the assets of Natural Pharmaceuticals, which makes active pharmaceutical ingredients for oncology drugs. The deal includes a manufacturing facility in British Columbia, Canada. Story

> Antisoma's AS1411 has gained orphan status in the U.S. and Europe for acute myeloid leukemia. Antisoma release

>  Dara BioSciences plans to raise $750,000 through the sale of shares. Report

Pharma News

> It's Connecticut's turn in the fallout-from-megamergers spotlight. Pfizer so far is keeping mum on just how its buyout of Wyeth will affect the two companies' facilities--and workers--in the state. Report

> A new lawsuit alleges that Schering execs sat on negative results from a Vytorin study. Report

> Generic rivals push J&J drug sales down 19 percent. Earnings report

Research News

> In a breakthrough, scientists have crafted a key part of a human jaw bone from stem cells and say the same process they used can be used to repair all types of bones in the human body. Item

> New sequencing technology has helped researchers analyze the DNA of a breast cancer genome from a single patient at three different stages of development, offering scientists a revealing look at how breast cancer cells mutate as the disease develops. Article

> Scientists have successfully treated diabetes with resveratrol. Report

> A single retrovirus appears to be prime culprit for chronic fatigue. Article

And Finally...Despite the severity of disease and the intensity of treatment, most patients in Australia and New Zealand who experienced respiratory failure as a result of 2009 influenza A(H1N1) and were treated with a system that adds oxygen to the patient's blood survived the disease, according to a new study. Release

Suggested Articles

After delivering a "positive surprise" in December, Biogen is painting a fuller picture of its lupus drug.

A new CRISPR technique neutralizes SARS-CoV-2 by scrambling the virus' genetic code. It could prove useful for fighting other viruses, like influenza.

The deal, which follows a bidding war with AcelRx, gives Melinta another approved antibiotic and potentially complementary R&D expertise.